Tier 4 — mechanistic

Resveratrol improves health and survival of mice on a high-calorie diet

Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R, Sinclair DA
Nature 2006 444(7117):337-342

Bibliography

PubMed
PMID 17086191
PubMed Central
PMC4990206
DOI
10.1038/nature05354
Funding
US National Institutes of Health and other public research grants (per journal disclosure); not stated as industry-sponsored.
Competing interests
Not stated as a specific conflict in the abstract; several authors (including senior author Sinclair) have since founded or advised companies commercialising sirtuin-activator compounds — a relevant historical context for later resveratrol commercial interest, though not a direct COI on this specific paper.

Study snapshot

DesignPreclinical study: high-calorie-diet mouse feeding trial with resveratrol supplementation
ModelMiddle-aged mice on a high-calorie diet
SampleNot applicable — preclinical animal study
InterventionDietary resveratrol supplementation in mice fed a high-calorie diet
DurationLong-term feeding study (through middle age)
EndpointsSurvival; Insulin sensitivity; IGF-1 levels; AMPK and PGC-1alpha activity; Mitochondrial number; Motor function; Gene expression pathway analysis

What the study showed, in plain terms

This landmark 2006 study found that resveratrol shifted the health of mice on a high-calorie diet toward that of mice on a normal diet, and significantly increased their survival. It proposed that resveratrol worked by activating a protein called SIRT1, launching over a decade of research into resveratrol as a calorie-restriction mimetic — though that specific mechanism has since been extensively debated.

Key findings

Resveratrol shifted the physiology of mice on a high-calorie diet toward that of standard-diet mice and significantly increased survival, with increased insulin sensitivity, reduced IGF-1, increased AMPK and PGC-1alpha activity, increased mitochondrial number, and improved motor function. The paper proposed SIRT1 activation as the underlying mechanism.

What this study can and cannot tell us

Preclinical mouse study only — no human data. The proposed direct SIRT1-activation mechanism has since been extensively contested by other research groups, who have had difficulty replicating direct SIRT1 activation in cell-free assays; some of the original signal may reflect assay artefacts rather than genuine target engagement.

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability